ClinicalTrials.gg
Not yet recruitingNCT07477951lungUpdated Mar 17, 2026

The Impact of Automatic Lung Recruitment Postoperative Pulmonary Complications

An interventional study of Automated recruitment maneuver (Auto-RM) in Acute Lung Injury, sponsored by Yongtao Sun. Not yet recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Yongtao Sun · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
19th of 31
58 · median 60
Started
2026
with 7 others
No phase
20 of 59
6 open now
Primary completion
2026-12
later than 8 of 19 live
Registered
54th of 59
by date

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 19th largest by planned enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2026, is one of 20 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 54th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

Study Background and Purpose As society ages, an increasing number of elderly patients undergo surgery. Following surgery, particularly abdominal procedures, patients are susceptible to lung-related issues such as atelectasis (lung collapse) and infection, collectively known as Postoperative Pulmonary Complications (PPCs). These complications are a major factor affecting the recovery of elderly patients.

One method of general anesthesia is called Total Intravenous Anesthesia (TIVA). This study aims to investigate whether using an automated lung recruitment function, a smart feature available on modern anesthesia machines, can help protect lung function and reduce complications in elderly patients undergoing laparoscopic surgery under TIVA. The goal is to identify safer and more effective methods for anesthesia care.

Study Design

This is a clinical research study. Eligible elderly patients who provide consent will be randomly assigned to one of two groups:

Study Group: The automated lung recruitment function on the anesthesia machine will be used to manage breathing during surgery.

Control Group: Current standard methods for breathing management will be used during surgery.

The primary goal is to observe and compare the blood oxygenation level 30 minutes after surgery (a key indicator of lung function) between the two groups. The investigators will also record the occurrence of any lung-related complications within the first 3 days after surgery.

What Will Participants Do?

If participants agree to participate, they will be asked to:

Sign an informed consent form.

Undergo some pre-operative assessments arranged by the research team.

Receive the corresponding breathing management method during surgery, as determined by random assignment.

Allow the research team to collect relevant medical data after surgery (e.g., blood gas analysis results, medical records). All data will be kept strictly confidential.

Participation does not involve any additional invasive procedures. All medical care and monitoring will adhere to the standard safety protocols required for the surgery, and may even be more meticulous.

Potential Benefits and Risks of the Study

Potential Benefits:

Direct Benefit: Participants will receive more precise monitoring and care for their respiratory function during and after surgery.

Societal Value: Data from their participation will contribute to developing better anesthesia strategies for future elderly patients, potentially improving their recovery outcomes.

Potential Risks and Protections:

The study intervention is integrated into standard anesthesia. The main risks are associated with routine anesthesia and surgery itself (e.g., temporary blood pressure fluctuations, low oxygen levels). These risks are possible in any similar surgical procedure.

The study will be conducted by experienced anesthesiologists with continuous, close monitoring. Comprehensive emergency plans are in place to ensure participant safety.

Participants have the right to withdraw from the study at any time, for any reason, without affecting their eligibility for any future standard medical care.

All personal information and study data will be kept strictly confidential. Data will be analyzed using coded identifiers only. Any published results will not contain information that could reveal the identity of participants.

03

Conditions studied

  • Acute Lung Injury

Browse trials for

Keywords

  • Automated recruitment maneuver (Auto-RM)
  • Total Intravenous Anesthesia (TIVA)
  • postoperative pulmonary complications (PPCs)
  • acute lung injury (ALI)
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged≥65 years
  • (ASA) grades I-III;
  • (BMI) between 18-30kg/m²
  • No history of drug allergy or abnormal anesthesia;
  • Patients undergoing laparoscopic gastrointestinal surgery, and operative time> 2 hours;
  • Participants with a preoperative oxygen saturation not \< 94%
  • Participants for whom extubation is planned in the operating room.
  • The assess respiratory risk in surgical patients in Catalonia (ARISCAT) score is 26-44 or > 44.

Exclusion criteria

Exclusion Criteria:

  • ALI or ARDS patient within 3 months; severe pulmonary dysfunction; severe ( \<50% of predicted value) or pulmonary hypertension;
  • classification: Class IV;
  • Chronic renal failure(\<30ml min-11.73m-2);
  • Severe liver disease;
  • Patients with confusion and cognitive dysfunction;
  • Severe coagulation disorders;
  • Patients with tracheal tubes transported to the ICU;
  • Other reasons;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • No intervention
    conventional ventilation group

    Total Intravenous Anesthesia (TIVA) + Volume-Controlled Ventilation (VCV) The procedure was performed with total intravenous anesthesia (TIVA) combined with volume-controlled ventilation (VCV). The settings for the lung-protective ventilation strategy were as follows: tidal volume was maintained at 6-8 mL/kg predicted body weight (PBW) (calculated as: 50 + 0.91 × \[height (cm) - 152.4\] for males; 45.5 + 0.91 × \[height (cm) - 152.4\] for females). The inspiratory-to-expiratory ratio was set at 1:2, and a positive end-expiratory pressure (PEEP) of 5 cmH₂O was applied intraoperatively. The ventilation rate was adjusted according to intraoperative end-tidal carbon dioxide (PetCO₂) to maintain PetCO₂ within the range of 35-50 mmHg.

  • Experimental
    Automated recruitment maneuver (Auto-RM) group

    Automated recruitment maneuvers (Auto-RM) were performed using the HuaSheng Lavender anesthesia machine at 10 min after intubation/laryngeal mask insertion and again 10 min before the end of surgery, in addition to TIVA with VCV. Using the PEEP incremental method in PCV mode (respiratory rate 10/min, I:E 1:1, driving pressure 10-15 cmH₂O), PEEP was increased by 5 cmH₂O every 30 s from baseline until peak pressure reached 40 cmH₂O. PEEP was then gradually decreased, and the level corresponding to the minimum driving pressure (DP = Pplat - PEEP) was recorded and maintained. Other ventilator settings were identical to the control group.

    Device: Automated recruitment maneuver (Auto-RM)

Interventions

  • DeviceAutomated recruitment maneuver (Auto-RM)

    In addition to total intravenous anesthesia (TIVA) combined with volume-controlled ventilation (VCV), an automated recruitment maneuver was performed using the HuaSheng Lavender intravenous anesthesia machine at 10 minutes after intubation or laryngeal mask insertion and again at 10 minutes before the end of surgery. The maneuver employed the PEEP incremental method as follows: the ventilator was set to pressure-controlled ventilation (PCV) mode with a respiratory rate of 10 breaths/min, an inspiratory-to-expiratory ratio of 1:1, and a controlled pressure maintained at 10-15 cmH₂O. Starting from the baseline PEEP level, PEEP was increased by 5 cmH₂O every 30 seconds until peak pressure reached 40 cmH₂O. Subsequently, PEEP was gradually decreased, and the PEEP level corresponding to the minimum driving pressure (DP = plateau pressure - PEEP) during the recruitment process was recorded and maintained intraoperatively.

06

What researchers measure

Primary outcomes

  1. oxygenation index (PaO₂/FiO₂ ratio) at 30 minutes after extubation

    Arterial blood samples were collected for blood gas analysis

    Time frame: 30 minutes after extubation

Secondary outcomes

  1. extubation time, duration of PACU stay after anesthesia

    The time interval from the end of surgery to successful tracheal extubation, and the interval from PACU admission to meeting discharge criteria and actual PACU discharge, were recorded. The former was recorded by the anesthesia nurse according to clock time, with timestamps automatically captured by the anesthesia information management system. The latter was documented by the PACU nurse, noting the specific times of admission and discharge.

    Time frame: until actual discharge from the PACU

  2. Incidence of postoperative shivering

    Postoperative shivering was assessed using the Wrench grading scale (0-4). Grade 0 indicated no shivering; Grade 1 indicated piloerection, peripheral vasoconstriction, or peripheral cyanosis without visible muscle tremor; Grade 2 indicated tremor confined to a single muscle group; Grade 3 indicated tremor involving multiple muscle groups; and Grade 4 indicated generalized gross muscular activity. Shivering was considered clinically significant (event) when the Wrench grade was ≥3. If such shivering persisted for more than 3 minutes, a rescue dose of meperidine was administered.

    Time frame: Day 1

  3. The incidence of pulmonary complications occurring within the first 7 days following surgery

    The occurrence of postoperative pulmonary complications (PPCs) during hospitalization, including pulmonary infection, acute respiratory failure, pleural effusion, atelectasis, pneumothorax, bronchospasm, aspiration pneumonia, and acute respiratory distress syndrome (ARDS), was assessed by reviewing electronic medical records, imaging systems, and laboratory databases. The incidence of individual postoperative pulmonary complications (PPCs) within 7 days after surgery was recorded, including atelectasis, pneumonia, and acute respiratory distress syndrome (ARDS). Each complication was defined according to standardized criteria (e.g., for pneumonia: new lung infiltrate plus fever \>38°C and leukocytosis). The occurrence of any PPC was considered an adverse outcome.

    Time frame: up to 7 days

  4. Incidence of postoperative hypoxemia (SpO₂ < 94%) within 24 hours after surgery

    Pulse oximetry monitoring was applied; the number of episodes, duration, and whether any interventions were taken were recorded.

    Time frame: Day 1

  5. QoR-15 (15-item Quality of Recovery) scores on postoperative days 1, 2, and 3

    QoR-15 scores were assessed on postoperative days 1, 2, and 3 using the 15-item Quality of Recovery (QoR-15) scale,range: 0-150, with higher scores indicating better recovery.

    Time frame: Days 1, 2, and 3

  6. all-cause mortality within 30 days after surgery

    Survival status was assessed daily during hospitalization. Patients discharged before postoperative day 30 were followed up by telephone on day 30. Deaths were verified through hospital records, death registries, or family reports.

    Time frame: up to 30 days

  7. Incidence of postoperative nausea and vomiting (PONV) at 24, 48, and 72 hours after surgery

    Nausea and vomiting were graded using the following scale: Grade 1: Mild nausea and abdominal discomfort, but no vomiting; Grade 2: Transient vomiting, ≤1 episode; Grade 3: Vomiting requiring antiemetic therapy, ≤2 episodes; Grade 4: Vomiting refractory to antiemetic therapy, ≥3 episodes.

    Time frame: Days 1, 2 and 3

  8. Postoperative NRS scores at 24, 48, and 72 hours

    Pain intensity was assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating more severe pain.

    Time frame: Days 1, 2 and 3

07

Study locations

1 site
08

References and documents

Publications

  • Ferrando C, Carraminana A, Pineiro P, Mirabella L, Spadaro S, Librero J, Ramasco F, Scaramuzzo G, Cervantes O, Garutti I, Parera A, Argilaga M, Herranz G, Unzueta C, Vives M, Regi K, Costa-Reverte M, Sonsoles Leal M, Nieves-Alonso J, Garcia E, Rodriguez-Perez A, Farina R, Cabrera S, Guerra E, Gallego-Ligorit L, Herrero-Izquierdo A, Valles-Torres J, Ramos S, Lopez-Herrera D, De La Matta M, Gokhan S, Kucur E, Mugarra A, Soro M, Garcia L, Sastre JA, Aguirre P, Salazar CJ, Ramos MC, Morocho DR, Trespalacios R, Ezequiel-Fernandez F, Lamanna A, Pia Cantatore L, Laforgia D, Bellas S, Lopez C, Navarro-Ripoll R, Martinez S, Vallverdu J, Jacas A, Yepes-Temino MJ, Belda FJ, Tusman G, Suarez-Sipmann F, Villar J; iPROVE-OLV Research Network Group. Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2024 Mar;12(3):195-206. doi: 10.1016/S2213-2600(23)00346-6. Epub 2023 Dec 5. PubMed 38065200 ↗
  • Chang YT, Shen CH. Total Intravenous Anesthesia and Postoperative Pulmonary Complications-Reply. JAMA Otolaryngol Head Neck Surg. 2023 Apr 1;149(4):376-377. doi: 10.1001/jamaoto.2022.4967. No abstract available. PubMed 36757716 ↗
  • Obara S, Oishi R, Nakano Y, Noji Y, Ebana H, Isosu T, Kurosawa S, Murakawa M. Update on the SedLine(R) algorithm for calculating the Patient State Index of older individuals during general anesthesia: a randomized controlled trial. Minerva Anestesiol. 2021 Jul;87(7):774-785. doi: 10.23736/S0375-9393.21.14929-6. Epub 2021 May 3. PubMed 33938673 ↗
  • Jonkman AH, Alcala GC, Pavlovsky B, Roca O, Spadaro S, Scaramuzzo G, Chen L, Dianti J, Sousa MLA, Sklar MC, Piraino T, Ge H, Chen GQ, Zhou JX, Li J, Goligher EC, Costa E, Mancebo J, Mauri T, Amato M, Brochard LJ; Pleural Pressure Working Group (PLUG). Lung Recruitment Assessed by Electrical Impedance Tomography (RECRUIT): A Multicenter Study of COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2023 Jul 1;208(1):25-38. doi: 10.1164/rccm.202212-2300OC. PubMed 37097986 ↗
  • Pei S, Wei W, Yang K, Yang Y, Pan Y, Wei J, Yao S, Xia H. Recruitment Maneuver to Reduce Postoperative Pulmonary Complications after Laparoscopic Abdominal Surgery: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Oct 1;11(19):5841. doi: 10.3390/jcm11195841. PubMed 36233708 ↗
  • Zhang YT, Han Y, Zhuang HJ, Feng AM, Jin L, Li XF, Yu H, Yu H. Effect of inspiratory oxygen fraction during driving pressure-guided ventilation strategy on pulmonary complications following open abdominal surgery: A randomized controlled trial. J Clin Anesth. 2024 Dec;99:111676. doi: 10.1016/j.jclinane.2024.111676. Epub 2024 Nov 6. PubMed 39509739 ↗
  • Hughes LM, Irwin MG, Nestor CC. Alternatives to remifentanil for the analgesic component of total intravenous anaesthesia: a narrative review. Anaesthesia. 2023 May;78(5):620-625. doi: 10.1111/anae.15952. Epub 2022 Dec 23. PubMed 36562193 ↗
  • Nimmo AF, Absalom AR, Bagshaw O, Biswas A, Cook TM, Costello A, Grimes S, Mulvey D, Shinde S, Whitehouse T, Wiles MD. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. Anaesthesia. 2019 Feb;74(2):211-224. doi: 10.1111/anae.14428. Epub 2018 Oct 31. PubMed 30378102 ↗
  • Young CC, Harris EM, Vacchiano C, Bodnar S, Bukowy B, Elliott RRD, Migliarese J, Ragains C, Trethewey B, Woodward A, Gama de Abreu M, Girard M, Futier E, Mulier JP, Pelosi P, Sprung J. Lung-protective ventilation for the surgical patient: international expert panel-based consensus recommendations. Br J Anaesth. 2019 Dec;123(6):898-913. doi: 10.1016/j.bja.2019.08.017. Epub 2019 Oct 3. PubMed 31587835 ↗
  • Wenzel V, Idris AH, Banner MJ, Kubilis PS, Band R, Williams JL Jr, Lindner KH. Respiratory system compliance decreases after cardiopulmonary resuscitation and stomach inflation: impact of large and small tidal volumes on calculated peak airway pressure. Resuscitation. 1998 Aug;38(2):113-8. doi: 10.1016/s0300-9572(98)00095-1. PubMed 9863573 ↗
  • Guldner A, Kiss T, Serpa Neto A, Hemmes SN, Canet J, Spieth PM, Rocco PR, Schultz MJ, Pelosi P, Gama de Abreu M. Intraoperative protective mechanical ventilation for prevention of postoperative pulmonary complications: a comprehensive review of the role of tidal volume, positive end-expiratory pressure, and lung recruitment maneuvers. Anesthesiology. 2015 Sep;123(3):692-713. doi: 10.1097/ALN.0000000000000754. PubMed 26120769 ↗
  • Campos LI, Mansfield D, Smith A, Kohli H, Sun D, Espinosa MH, Dy V. Carbon dioxide volume and intra-abdominal pressure determination before the creation of a pneumoperitoneum. Surg Laparosc Endosc. 1995 Apr;5(2):100-4. PubMed 7773453 ↗
  • Takiguchi S, Fujiwara Y, Yamasaki M, Miyata H, Nakajima K, Sekimoto M, Mori M, Doki Y. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg. 2013 Oct;37(10):2379-86. doi: 10.1007/s00268-013-2121-7. PubMed 23783252 ↗
  • Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010 Mar;251(3):417-20. doi: 10.1097/SLA.0b013e3181cc8f6b. PubMed 20160637 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • 江洪洋,樊世文,刘铁龙,等.个体化PEEP联合定期肺复张对行腹腔镜结直肠癌根治术老年患者术后肺不张的影响[J].天津医药,2024,52(02):182-187.
  • Spraider P, Abram J, Wally D, Bernardi D, Augustin F, Hell T, Tscholl P, Dejaco H. Low versus High Fraction of Inspired Oxygen During Lung Separation in Thoracic Surgery: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2025 Jul;39(7):1746-1754. doi: 10.1053/j.jvca.2025.03.031. Epub 2025 Mar 20. PubMed 40210503 ↗
  • 刘宇锋,赵智慧.不同吸入氧浓度对腹腔镜结直肠癌根治术老年患者氧合的影响[J].内蒙古医学杂志,2023,55(01):18-20+24.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 8 months is below that.

Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 17, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477951
Lead sponsor
Yongtao Sun
Responsible party
Yongtao Sun (professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Mar 17, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Liu Mengjie, Doctoral Degree
Contact
liumengjie31@163.com
0531-89268535 ext. +8615628920681

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion